Company: APXIF
Filing Date: 2025-06-11
Form Type: 10-Q
Source: 0001213900-25-053185
Chunk: 53

Company: APx Acquisition Corp. I
Filing Date: 2025-06-11
Form: 10-Q
Item: Part I, Item 1
Chunk 53
---
illary documents or agreements.

On August 27, 2024,
Parent, MultiplAI and the MultiplAI Shareholders (with the consent of the Company) terminated the MultiplAI SPA.

Voting and Support Agreement

Concurrently with the
execution of the Business Combination Agreement, the Company, Templar Sponsor, OmnigenicsAI and the Parent entered into a Voting and Support
Agreement (the “Support Agreement”), pursuant to which, among other things, the Templar Sponsor agreed to vote any of the
Sponsor Current Shares (as defined in the Support Agreement) and any SPAC Ordinary Shares held by the Sponsor in favor of the Proposed
Business Combination, and Parent agreed to vote any of the Parent Subject Shares (as defined in the Support Agreement) in favor of the
Proposed Business Combination.

Additionally, the Support
Agreement contains certain covenants to be performed by the parties thereto following the Closing.

The foregoing description
of the Support Agreement is qualified in its entirety by reference to the full text of the Support Agreement, a copy of which is included
as an exhibit to this Quarterly Report.

 35

Backstop Agreement

Concurrently with the
execution of the Business Combination Agreement, Theo I SCSp, a special limited partnership (société en commandite spéciale)
governed by the laws of the Grand Duchy of Luxembourg and a shareholder of Parent (“Theo”), OmnigenicsAI and the Company entered
into the Backstop Agreement, pursuant to which, among other things, subject to and conditioned upon the occurrence of the Closing, Theo
shall be obligated to obtain the amount (if any) by which $10,000,000 exceeds the aggregate amount of cash on deposit in the Trust Account
(including any interest earned on the funds held in the Trust Account) that will remain after payment in full of the SPAC Shareholder
Redemption Amount to SPAC Shareholders pursuant to their exercise of the SPAC Shareholder Redemption Right (assuming no SPAC Transaction
Expenses have been paid from the Trust Account), and the aggregate amount of cash at the Company or OmnigenicsAI in connection with any
PIPE Investment for the benefit of the Company and OmnigenicsAI on the Closing Date, by one or more of the following methods: (i) making
on the Closing Date, directly or indirectly, a capital contribution in cash to OmnigenicsAI and, in exchange for such capital contribution,
subscribing for and being issued by Omn